AAPL343.57+1.57 (+0.46%) ▲|ABBV285.36+1.96 (+0.69%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.63+4.71 (+2.09%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.29+3.93 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.60-0.27 (-0.09%) ▼|BA190.04+1.31 (+0.69%) ▲|BAC51.23-0.48 (-0.92%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,133.87+13.09 (+1.17%) ▲|BMY59.84-0.74 (-1.21%) ▼|BNY143.25+1.16 (+0.82%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.23+1.02 (+0.83%) ▲|CAT730.79-4.85 (-0.66%) ▼|CL94.08+1.41 (+1.52%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.68-6.06 (-2.46%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.37-0.21 (-0.23%) ▼|CVX224.97+5.65 (+2.58%) ▲|DE641.85-8.82 (-1.36%) ▼|DHR229.03-2.47 (-1.07%) ▼|DIS110.57-0.11 (-0.10%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.45-0.70 (-0.43%) ▼|FDX293.53-2.01 (-0.68%) ▼|GD344.15+7.12 (+2.11%) ▲|GE313.94+1.94 (+0.62%) ▲|GEV921.02-5.42 (-0.59%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS880.60-10.69 (-1.20%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.60+2.32 (+0.92%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.86+1.86 (+2.02%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.26+5.65 (+0.45%) ▲|LMT551.73+19.09 (+3.58%) ▲|LOW197.35+1.63 (+0.83%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.24+0.92 (+0.15%) ▲|MCD242.94+0.44 (+0.18%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.76-0.69 (-0.72%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.72-0.61 (-0.37%) ▼|MO75.10+1.26 (+1.71%) ▲|MRK145.93+0.74 (+0.51%) ▲|MS180.53-1.57 (-0.86%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.79+0.83 (+1.05%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.02 (-0.04%) ▼|NOW141.95-6.62 (-4.46%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.22-6.25 (-4.65%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.57+0.13 (+0.44%) ▲|PG159.33+2.25 (+1.43%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM204.93+5.03 (+2.52%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.43-0.07 (-0.30%) ▼|TMO690.37-6.12 (-0.88%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|AAPL343.57+1.57 (+0.46%) ▲|ABBV285.36+1.96 (+0.69%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.63+4.71 (+2.09%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.29+3.93 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.60-0.27 (-0.09%) ▼|BA190.04+1.31 (+0.69%) ▲|BAC51.23-0.48 (-0.92%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,133.87+13.09 (+1.17%) ▲|BMY59.84-0.74 (-1.21%) ▼|BNY143.25+1.16 (+0.82%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.23+1.02 (+0.83%) ▲|CAT730.79-4.85 (-0.66%) ▼|CL94.08+1.41 (+1.52%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.68-6.06 (-2.46%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.37-0.21 (-0.23%) ▼|CVX224.97+5.65 (+2.58%) ▲|DE641.85-8.82 (-1.36%) ▼|DHR229.03-2.47 (-1.07%) ▼|DIS110.57-0.11 (-0.10%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.45-0.70 (-0.43%) ▼|FDX293.53-2.01 (-0.68%) ▼|GD344.15+7.12 (+2.11%) ▲|GE313.94+1.94 (+0.62%) ▲|GEV921.02-5.42 (-0.59%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS880.60-10.69 (-1.20%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.60+2.32 (+0.92%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.86+1.86 (+2.02%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.26+5.65 (+0.45%) ▲|LMT551.73+19.09 (+3.58%) ▲|LOW197.35+1.63 (+0.83%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.24+0.92 (+0.15%) ▲|MCD242.94+0.44 (+0.18%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.76-0.69 (-0.72%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.72-0.61 (-0.37%) ▼|MO75.10+1.26 (+1.71%) ▲|MRK145.93+0.74 (+0.51%) ▲|MS180.53-1.57 (-0.86%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.79+0.83 (+1.05%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.02 (-0.04%) ▼|NOW141.95-6.62 (-4.46%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.22-6.25 (-4.65%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.57+0.13 (+0.44%) ▲|PG159.33+2.25 (+1.43%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM204.93+5.03 (+2.52%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.43-0.07 (-0.30%) ▼|TMO690.37-6.12 (-0.88%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|
21.2 C
New York
Friday, October 16, 2026

Tag: tumors

newssourceFORcompanycontentinformation1releasesmarket

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

PROCURE PROTON THERAPY CENTER CELEBRATES JOSEPH AS ITS 8,000TH PATIENT

SOMERSET, N.J., June 12, 2026 /PRNewswire/ -- When Joseph, a military veteran diagnosed with prostate cancer, became ProCure Proton Therapy Center's 8,000th patient, the milestone...

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain...

TAIPEI, June 11, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil...

GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8

NEW TAIPEI CITY, June 10, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial...

Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 10, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the...

Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company

Minami Maeda appointed as CEO to drive faster, more focused execution toward U.S. commercial launchMickey Mikitani will continue to provide strategic direction and remains...

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

SHANGHAI and HONG KONG, June 10, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to...

Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer

OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch...

Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution

StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundariesWhole-transcriptome profiling across a large tissue capture area...

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for...

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTumors

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers